bone marker

bone marker

Any biochemical marker that indicates bone breakdown, which can be used to predict individual fracture risk when bone mineral density measurement does not provide a clear answer.

Bone markers
Bone formation markers
• Serum total alkaline phosphatase;
• Serum bone—specific alkaline phosphatase;
• Serum osteocalcin;
• Serum type-1 procollagen.

Bone resorption markers
• Urine hydroxyproline;
• Urine total pyridinoline (PYD);
• Urine free deoxypyridinoline (DPD);
• Urine collagen type-1 cross-linked N-telopeptide (NTX);
• Urine or serum collagen type-1 cross-linked C-telopeptide (CTX);
• Bone sialoprotein (BSP);
• Tartrate-resistant acid phosphatase 5b.

bone marker

Lab medicine Any protein degradation product that indicates bone breakdown. See N-telopeptides.
References in periodicals archive ?
It increases the growth of cells called osteoblasts, which help build your bones, and increases expression of collagen and bone marker proteins.
We show that this prevention in areal bone mineral density and micro-CT parameters results from the stimulation of bone formation, demonstrable in vivo by histomorphometry, bone marker measurements, and quantitative PCR.
These data give an insight into the bone marker response to very short training protocols, the data suggest at early time points in a training protocol bone formation and bone resorption are both suppressed.
Sedentary SCI subjects in this study had higher bone marker formation (BAP) rates than the active SCI subjects, a result which contrasts with studies in able-bodied athletes, in whom exercise has had a positive influence on bone density formation (9,10).
For a bone marker to be useful in assessing the rate of bone turnover and monitoring therapy, the following attributes are required:
Menopause was the chief factor influencing the variations in bone marker measurements in women, with the mean level of S-OC and S-BAP increasing by 21% and 41%, respectively.
Bone marker results were adjusted for changes in plasma volume as follows:
Measurements of biochemical markers will be assessed to determine whether bone marker turnover is an effective predictor of the skeletal response to combination therapy.
Competitive, technology and sales analyses are provided for: central and peripheral bone densitometry systems; bone marker assays; prophylactic and therapeutic drugs (hormone replacement therapy, selective estrogen modulators, bisphosphonates, calcitonins, parathyroid hormones, and emerging agents), internal fracture fixation and hip replacement products, and kyphoplasty devices, bone cements and cement delivery systems used to perform PVA, among others.
As part of its market leading bone marker portfolio, Roche Diagnostics also offers the Elecsys Beta-CrossLaps test, a bone resorption marker, which monitors the efficacy of medications that slow or stop the natural process that dissolves bone tissue given to postmenopausal osteoporatic women.
One important element of the program -- the bone marker study that will assess the efficacy of Cenestin in reducing the loss of bone caused by menopause -- has begun, and results are anticipated to be published early next year.
One important element of these clinical trials, the bone marker study that will assess the rate at which the estrogens in Cenestin are absorbed into bone tissue, has begun, and some results may be published next year.